In this webinar, Dr. Naz Dastgir, Executive Medical Director and Clinical Development Lead for RGX-202 at REGENXBIO, shared information on the active and enrolling AFFINITY DUCHENNE trial and how families can obtain additional information about RGX-202 and potential clinical trial participation.
Watch HERE
The post REGENXBIO AFFINITY DUCHENNE: Trial of Investigational RGX-202 Gene Therapy appeared first on CureDuchenne.